The presentations will take place at the 58th American Society of Hematology (ASH) Annual Meeting, to be held in San Diego, California, Dec. 3–6.
Minimum residual disease (MRD) refers to small numbers of lymphoid cancer cells that may remain in the body after treatment, and eventually cause the disease to relapse. These residual cells cause no symptoms, and the cells are present at such low levels that doctors may not detect them with routine tests.
The clonoSEQ MRD test can detect disease at levels as low as 1 cancer cell per 1 million white blood cells (WBC), the company reports on its website. This ability, it says, makes the test up to 100 times more sensitive than other methods used to detect residual cancer cells.
“Providing a diagnostic assay that is ultra-sensitive and standardized to determine treatment response and predict outcomes in people with lymphoid cancers is a priority for Adaptive,” Harlan Robins, the company’s chief scientific officer and co-founder, said in a press release. “Data presented during ASH demonstrate the breadth of our technology’s capability to predict which patients are at greatest risk of relapse and serve as a reliable surrogate endpoint in pivotal clinical trials.”
Adaptive Biotechnologies will give eight oral and 10 poster presentations at the ASH meeting, showing data including MRD assessment and T-cell repertoire characterization in patients with five different hematological cancers: chronic lymphocytic leukemia, acute myeloid leukemia, multiple myeloma, aplastic anemia, and mantle cell lymphoma.
The abstract, “Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens,” to be presented Dec. 5, describes a study in 17 patients with untreated mantle cell lymphoma. Investigators sought to identify human lymphoma tumor antigens (molecules that trigger an immune response) through genomic and protein examination of particular peptides that can trigger immune T-cell activity.
The researchers found 66 peptides expressed by the lymphoma cells that could be used, by so-called antigen presenting cells, to activate specific subsets of T-cells. This suggests that these peptides can be used in T-cell mediated therapies to drive strong immune responses against the cancer cells.
Another presentation, “Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma,” on Dec. 4, will show data from patients with mantle cell lymphoma (MCL) undergoing immune vaccination.
Its researchers report that levels of circulating tumor DNA can be used as a biomarker to predict the immune system response after administration of dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) plus rituximab (DA-EPOCH-R), followed by a cancer vaccine in patients with MCL.
More details about the company’s planned ASH presentations can be found here.